Trial · NCT07514429
Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial
NCT07514429, Phase 2, Not yet recruiting, Ju Hyun Shim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial. Trials, record NCT07514429. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07514429
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial
- NCT number
- NCT07514429
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Ju Hyun Shim
- Conditions
- Carcinoma, Hepatocellular, Lenvatinib, Treatment Failure
- Interventions
- Regorafenib (BAY 73-4506)
- First posted
- 2026-04-07
- Last updated
- 2026-04-07
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | progression free survival | From date of first dose until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 36 months. | Tumor assessments every 12 weeks (±7 days) after treatment discontinuation without documented progression until progression, death, or end of follow-up, whichever occurs first. |
| Secondary | Overall survival | From date of first dose until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 36 months. | Survival follow-up assessments are conducted every 12 weeks (±7 days) after treatment discontinuation due to disease progression or withdrawal until death or end of follow-up. |
| Secondary | time to progression | From treatment initiation until first documented progression or start of subsequent systemic anticancer therapy, assessed up to 36 months. | Baseline and scheduled tumor imaging assessments every 12 weeks (±7 days) thereafter (date of documented PD per RECIST v1.1). |
| Secondary | objective response rate | From treatment initiation until first documented progression or start of subsequent systemic anticancer therapy, assessed up to 36 months. | Assessment of Best Overall Response (CR/PR) at scheduled tumor imaging time points (every 12 weeks ±7 days) from treatment initiation until first PD or start of subsequent systemic anticancer therapy. |
| Secondary | disease control rate | From treatment initiation until first documented progression or start of subsequent systemic anticancer therapy, assessed up to 36 months. | Assessment of Best Overall Response (CR/PR/SD) at scheduled tumor imaging time points (every 12 weeks ±7 days) from treatment initiation until first PD or start of subsequent systemic anticancer therapy. |
| Secondary | Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | From first dose of study drug until 30 days after last dose, assessed up to 24 months. | Adverse events will be graded according to the NCI CTCAE version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07514429
GET https://conductscience.org/api/trials/v1/NCT07514429/registered